Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin Kaiser, Matthew Jenner, Andrew Hall et al.|Journal of Clinical Oncology|2023Cited by 114
MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Martin Kaiser, Debbie Sherratt et al.|BMJ Open|2021Cited by 27
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myelomaMihaela Rata, Christina Messiou, Alexander King et al.|Insights into Imaging|2022Cited by 23
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.Martin Kaiser, Matthew Jenner, Andrew Hall et al.|Journal of Clinical Oncology|2021Cited by 17
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Christina Messiou, Alina Dragan et al.|Insights into Imaging|2023Cited by 15